Inozyme Pharma (INZY) Competitors $1.25 -0.02 (-1.18%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 02/21/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends INZY vs. MBX, ACB, TERN, FHTX, TSHA, CYRX, ANNX, CRVS, TRVI, and CMPSShould you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Inozyme Pharma vs. MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Taysha Gene Therapies Cryoport Annexon Corvus Pharmaceuticals Trevi Therapeutics COMPASS Pathways Inozyme Pharma (NASDAQ:INZY) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Does the media refer more to INZY or MBX? In the previous week, MBX Biosciences had 5 more articles in the media than Inozyme Pharma. MarketBeat recorded 6 mentions for MBX Biosciences and 1 mentions for Inozyme Pharma. MBX Biosciences' average media sentiment score of 1.62 beat Inozyme Pharma's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inozyme Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community prefer INZY or MBX? Inozyme Pharma received 51 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 87.30% of users gave Inozyme Pharma an outperform vote. CompanyUnderperformOutperformInozyme PharmaOutperform Votes5587.30% Underperform Votes812.70%MBX BiosciencesOutperform Votes4100.00% Underperform VotesNo Votes Which has stronger valuation & earnings, INZY or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInozyme PharmaN/AN/A-$71.17M-$1.56-0.80MBX BiosciencesN/AN/AN/AN/AN/A Is INZY or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Inozyme Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Inozyme PharmaN/A -88.42% -57.02% MBX Biosciences N/A N/A N/A Do analysts rate INZY or MBX? Inozyme Pharma presently has a consensus target price of $18.33, suggesting a potential upside of 1,360.82%. MBX Biosciences has a consensus target price of $37.25, suggesting a potential upside of 242.37%. Given Inozyme Pharma's higher possible upside, equities research analysts plainly believe Inozyme Pharma is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inozyme Pharma 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of INZY or MBX? 88.3% of Inozyme Pharma shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryInozyme Pharma and MBX Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INZY vs. The Competition Export to ExcelMetricInozyme PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.62M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.806.1326.4618.82Price / SalesN/A311.27456.6780.61Price / CashN/A67.8344.0437.47Price / Book0.556.747.634.64Net Income-$71.17M$138.11M$3.18B$245.69M7 Day Performance-8.39%-2.43%-1.91%-2.66%1 Month Performance-3.46%-1.91%-0.19%-2.15%1 Year Performance-77.35%-5.03%16.70%12.90% Inozyme Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INZYInozyme Pharma2.979 of 5 stars$1.26-1.2%$18.33+1,360.8%-77.7%$80.62MN/A-0.8050News CoverageMBXMBX Biosciences2.59 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.5175 of 5 stars$6.31-4.7%N/A+73.2%$346.17M$200.35M126.231,073Gap UpTERNTerns Pharmaceuticals4.3932 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7039 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Positive NewsTSHATaysha Gene Therapies2.3561 of 5 stars$1.63+0.6%$6.63+306.4%-36.1%$334.05M$15.45M2.59180CYRXCryoport2.5802 of 5 stars$6.73+0.4%$12.29+82.6%-61.4%$332.66M$233.26M-1.991,170Positive NewsANNXAnnexon2.5512 of 5 stars$3.07+2.0%$15.80+414.7%-42.8%$327.23MN/A-2.9260News CoverageGap UpCRVSCorvus Pharmaceuticals1.9049 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.59MN/A-5.2530News CoverageTRVITrevi Therapeutics2.7567 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoveragePositive NewsGap UpCMPSCOMPASS Pathways1.7049 of 5 stars$4.57+3.4%$30.60+569.6%-57.6%$312.68MN/A-2.08120 Related Companies and Tools Related Companies MBX Biosciences Alternatives Aurora Cannabis Alternatives Terns Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Taysha Gene Therapies Alternatives Cryoport Alternatives Annexon Alternatives Corvus Pharmaceuticals Alternatives Trevi Therapeutics Alternatives COMPASS Pathways Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INZY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INZY Stock Alerts